Health utilities for non-melanoma skin cancers and pre-cancerous lesions: A systematic review.
Journal
Skin health and disease
ISSN: 2690-442X
Titre abrégé: Skin Health Dis
Pays: England
ID NLM: 9918227353706676
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
10
04
2021
revised:
20
05
2021
accepted:
22
05
2021
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Non-melanoma skin cancers (NMSCs) are common and consume many healthcare resources. A health utility is a single preference-based value for assessing health-related quality of life, which can be used in economic evaluations. There are scarce data on health utilities for NMSCs. Using a systematic review approach, we synthesized the current data on NMSC-related health utilities. A systematic review of studies of NMSC-related health utilities was conducted in Medline, Embase, and Cochrane databases. Data were extracted based on the protocol and a quality assessment was performed for each study. The protocol resulted in 16 studies, involving 121 621 participants. Mean utility values across the studies ranged from 0.56 to 1 for undifferentiated NMSC, 0.84 to 1 for actinic keratosis, 0.45 to 1 for squamous cell carcinoma, and 0.67 to 1 for basal cell carcinoma. There was considerable variability in utilities by type of cancer, stage of diagnosis, time to treatment, treatment modality, and quality of life instrument or method. Utility values were predominantly based on the EuroQol 5-dimension instrument and ranged from 0.45 to 0.96, while other measurement methods produced values ranging from 0.67 to 1. Lower utility values were observed for advanced cancers and for the time period during and immediately after treatment, after which values gradually returned to pre-treatment levels. Most utility values clustered around relatively high values of 0.8 to 1, suggesting small decrements in quality of life associated with most NMSCs and their precursors. Variability in utilities indicates that careful characterization is required for measures to be used in economic evaluations.
Sections du résumé
Background
UNASSIGNED
Non-melanoma skin cancers (NMSCs) are common and consume many healthcare resources. A health utility is a single preference-based value for assessing health-related quality of life, which can be used in economic evaluations. There are scarce data on health utilities for NMSCs.
Objectives
UNASSIGNED
Using a systematic review approach, we synthesized the current data on NMSC-related health utilities.
Methods
UNASSIGNED
A systematic review of studies of NMSC-related health utilities was conducted in Medline, Embase, and Cochrane databases. Data were extracted based on the protocol and a quality assessment was performed for each study.
Results
UNASSIGNED
The protocol resulted in 16 studies, involving 121 621 participants. Mean utility values across the studies ranged from 0.56 to 1 for undifferentiated NMSC, 0.84 to 1 for actinic keratosis, 0.45 to 1 for squamous cell carcinoma, and 0.67 to 1 for basal cell carcinoma. There was considerable variability in utilities by type of cancer, stage of diagnosis, time to treatment, treatment modality, and quality of life instrument or method. Utility values were predominantly based on the EuroQol 5-dimension instrument and ranged from 0.45 to 0.96, while other measurement methods produced values ranging from 0.67 to 1. Lower utility values were observed for advanced cancers and for the time period during and immediately after treatment, after which values gradually returned to pre-treatment levels.
Conclusions
UNASSIGNED
Most utility values clustered around relatively high values of 0.8 to 1, suggesting small decrements in quality of life associated with most NMSCs and their precursors. Variability in utilities indicates that careful characterization is required for measures to be used in economic evaluations.
Identifiants
pubmed: 35663144
doi: 10.1002/ski2.51
pii: SKI251
pmc: PMC9060093
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e51Informations de copyright
© 2021 The Authors. Skin Health and Disease published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Eur Arch Otorhinolaryngol. 2014 Nov;271(11):3011-9
pubmed: 24337900
Clin Transl Oncol. 2015 Jul;17(7):497-503
pubmed: 25643667
J Eur Acad Dermatol Venereol. 2018 Jul;32(7):1138-1146
pubmed: 29150868
Value Health. 2019 Mar;22(3):267-275
pubmed: 30832964
Br J Dermatol. 2012 May;166(5):1069-80
pubmed: 22251204
N Engl J Med. 2018 Jul 26;379(4):341-351
pubmed: 29863979
Br J Dermatol. 2018 Feb;178(2):384-393
pubmed: 29077983
Prev Med. 2016 Dec;93:177-182
pubmed: 27713103
Eur J Cancer. 2016 Aug;63:41-52
pubmed: 27267144
J Skin Cancer. 2019 Jun 26;2019:4798510
pubmed: 31346477
Med Care. 1996 Jul;34(7):702-22
pubmed: 8676608
Aust N Z J Public Health. 2018 Feb;42(1):86-91
pubmed: 29168287
J Dtsch Dermatol Ges. 2017 Nov;15(11):1090-1100
pubmed: 29106018
Skin Health Dis. 2021 Jun 04;1(3):e51
pubmed: 35663144
Future Oncol. 2015 Nov;11(22):2967-74
pubmed: 26466906
J Invest Dermatol. 2012 Jul;132(7):1785-90
pubmed: 22418874
Australas J Dermatol. 2015 Feb;56(1):70-6
pubmed: 25196191
Am J Epidemiol. 2010 Jan 1;171(1):123-8
pubmed: 19969529
J Dermatolog Treat. 2016 Oct;27(5):450-5
pubmed: 27052110
J Invest Dermatol. 2007 Dec;127(12):2726-39
pubmed: 17989733
Dermatol Surg. 2009 Nov;35(11):1776-87
pubmed: 19737291
Pharmacoeconomics. 2015 Nov;33(11):1101-5
pubmed: 26133293
Sci Rep. 2021 Feb 22;11(1):4337
pubmed: 33619293
Dermatol Surg. 2020 Mar;46(3):327-334
pubmed: 31397784
Health Qual Life Outcomes. 2015 Jul 29;13:111
pubmed: 26220553
Australas J Dermatol. 2015 Nov;56(4):258-67
pubmed: 25716064
Dermatol Online J. 2006 Sep 08;12(5):7
pubmed: 16962022
Pharmacoeconomics. 2009;27(9):767-79
pubmed: 19757870
Value Health. 2006 Mar-Apr;9(2):65-7
pubmed: 16626409
J Cutan Med Surg. 2008 May-Jun;12(3):102-6
pubmed: 18544291
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
BMC Dermatol. 2013 Oct 29;13:13
pubmed: 24164857
Pharmacoeconomics. 2000 Feb;17(2):151-65
pubmed: 10947338
Med Decis Making. 2006 Jul-Aug;26(4):410-20
pubmed: 16855129
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Med Decis Making. 2018 Nov;38(8):954-967
pubmed: 30226101
Arch Dermatol Res. 2013 Nov;305(9):845-50
pubmed: 23604961
Dermatol Ther (Heidelb). 2019 Sep;9(3):505-510
pubmed: 31165365
Qual Life Res. 2017 Nov;26(11):3025-3034
pubmed: 28601958
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
An Bras Dermatol. 2019 Jul 29;94(3):304-312
pubmed: 31365659
Med Decis Making. 2011 Nov-Dec;31(6):800-4
pubmed: 21422468
Dermatology. 2020;236(2):133-142
pubmed: 31434078
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
J Invest Dermatol. 2017 Nov;137(11):2309-2315
pubmed: 28736229
Lancet. 1988 Apr 9;1(8589):795-7
pubmed: 2895318
Dermatol Clin. 2012 Apr;30(2):231-6, xiii
pubmed: 22284137
Value Health. 2013 Jan-Feb;16(1):202-10
pubmed: 23337232
BMJ Open. 2020 Feb 26;10(2):e034388
pubmed: 32107270
Value Health. 2018 May;21(5):605-611
pubmed: 29753359
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
Laryngoscope. 2007 Mar;117(3):399-405
pubmed: 17334300
J Med Econ. 2013;16(6):777-83
pubmed: 23621505
Pharmacoeconomics. 2010;28(11):1055-64
pubmed: 20936887
Dermatol Surg. 2004 Apr;30(4 Pt 1):525-9
pubmed: 15056143
J Eur Acad Dermatol Venereol. 2020 Mar;34(3):491-501
pubmed: 31419362
J Investig Dermatol Symp Proc. 2004 Mar;9(2):160-8
pubmed: 15083784
J Am Acad Dermatol. 2011 Jun;64(6):1051-9
pubmed: 21255868
Laryngoscope. 2005 Jul;115(7):1178-85
pubmed: 15995503
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Surg Res. 2019 Mar;235:308-314
pubmed: 30691811
Med J Aust. 2012 Nov 19;197(10):565-8
pubmed: 23163687
Br J Dermatol. 2014 Dec;171(6):1443-50
pubmed: 25039853
Med J Aust. 2007 Aug 20;187(4):210-4
pubmed: 17708722
Adv Ther. 2015 May;32(5):455-76
pubmed: 26006101
Med J Aust. 2006 Sep 4;185(5):255-8
pubmed: 16948620
Med Decis Making. 2003 Nov-Dec;23(6):480-8
pubmed: 14672108